Bardo SPV 1 Investment Overview
Through The Bardo Foundation, I spend my time at the frontier of oncology research: new technologies, new biology, new approaches to how cancer is diagnosed and treated. I have seen a lot come across my desk. CureWise stands out.
My family is investing directly. I can allocate an additional $500,000 through an SPV, and I am opening that to people in my network.
Cancer science keeps advancing, but patients and clinicians still struggle to turn that progress into treatment that can actually be pursued, coordinated, justified, and paid for. Records are fragmented. Molecular insights are underused. Once care moves beyond standard pathways, decisions often fragment, stall, or are denied.
CureWise supports patients and families facing complex cancer decisions by bringing together the full medical record, tumor genomics, and current clinical evidence into a structured longitudinal view.
Understand
Imports records from 55,000+ US providers. Structures medical history, labs, imaging, and genomics into one longitudinal view.
Discover
Multi-model AI reasoning evaluates treatment options, matches 15,000+ active clinical trials, and surfaces evidence beyond standard care.
Advocate
Produces physician briefs, question lists, visit prep materials, insurance appeal support, and care coordination tools.
AI Threshold Crossed
AI reasoning can now synthesize complex medical records with clinical evidence at the level required for precision oncology decision support.
CMS Reimbursement
New Principal Illness Navigation codes create a revenue pathway that did not exist two years ago, directly aligned with what CureWise enables.
Patient Data Access
The 21st Century Cures Act mandates patient data access via API. CureWise already imports records from 55,000+ US providers.
Delivery Gap Widening
Precision medicine is outpacing the delivery system's ability to act on it. That gap is exactly where CureWise sits.
Steve Brown's house burned down in the LA fires in January 2025. That displacement led to new doctors with fresh eyes, and a diagnosis of aggressive blood cancer that a year of earlier appointments had missed. The fire saved his life.
He fed his medical records to AI agents. They surfaced what his doctors had overlooked in minutes. Then they guided him to a targeted therapy, off-label and only used at top research centers, that proved far more effective than standard of care. He is now in remission.
He kept building. Finding the right doctors. Monitoring for recurrence. Searching clinical trials. Fighting insurance denials. Every one of those challenges became a product capability. That is the origin of CureWise.
I have spent many hours with Steve in person. His conviction comes from lived experience, and that experience shaped every part of this platform.
Platform in early access. SAFE instrument on Wilson Sonsini form. Last capital in before Series A.
Steve Brown
Stanford physicist, serial healthcare entrepreneur, cancer patient. Founded Health Hero Network, established VA/CMS reimbursement. Sold two startups to global tech companies. Chief AI Officer to Peter Diamandis. 200+ patents.
Dr. Ran Goshen, MD, PhD
20+ years in precision medicine and digital health. Founded two personalized oncology companies. Co-founded Shoni Health Ventures at Sheba Medical Center. MD and PhD, Hebrew University of Jerusalem.
Lisa Booth
20+ years scaling teams and products across technology and healthcare. Senior roles at Avanade, Julep Beauty, Point B, and Accenture.
Hiren Kavad
Extensive experience building ML and AI-driven products at scale. Led delivery across AI agents, automation platforms, and enterprise AI systems.
CureWise is raising at a $15M pre-money valuation cap. The scenarios below illustrate potential returns at various exit valuations, before dilution from future rounds.
Comparables: Doximity (~$4.3B), Hims & Hers (~$5.6B), Sword Health (~$4.6B), Hinge Health (~$3.1B), Function Health (~$2.5B). These are illustrative only and do not represent projected outcomes.
- Founder-market fit. Steve Brown was diagnosed with aggressive cancer, built CureWise to navigate his own treatment, and is now in remission. I have spent many hours with him in person.
- Immediate patient impact. AI that turns fragmented records, labs, imaging, and genomics into a structured care path. Matches patients against 15,000+ active clinical trials.
- Massive market. Over 2 million new cancer diagnoses per year in the US alone. 18+ million Americans living with or beyond cancer. $250B+ spent annually.
- Strong foundation. $5M seed round, $3.85M already closed. Experienced clinical and technical team. 6 patent applications filed. 1,800+ person waitlist.
- Mission-aligned. Directly connected to what I see every day in pediatric oncology research through The Bardo Foundation.
| Company | CureWise, Inc. (Delaware C-Corp) |
| Instrument | SAFE · $15M Pre-Money Valuation Cap |
| Target Raise | $500,000 |
| Minimum Investment | $25,000 |
| Management Fee | None |
| Performance Allocation | 20% carry over return of capital, allocated entirely to The Bardo Foundation |
I am not taking any fees on this vehicle. If this investment works, the performance allocation supports childhood cancer research through The Bardo Foundation. If it doesn't, nobody paid fees along the way.
A confidential investment memo with full details on CureWise, financials, and risks is available on request.
Request Investment Memo